Pipeline and Commercial Insight: Pediatric and Adolescent Vaccines

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2007-07-23

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The pediatric and adolescent vaccines market encompasses many different classes. DTP and MMR combinations continue to form the mainstay of childhood immunization; however, their growth potential is limited. The key opportunities lie in novel, innovative additions to established schedules, particularly pneumococcal (Prevnar), conjugated meningococcal (Menactra) and HPV (Gardasil) vaccines.


Scope

  • Strategic analysis of the pediatric and adolescent vaccines market across the seven major markets and of key companies in the sector
  • Thorough assessment of underlying commercial and clinical influencers shaping the pediatric and adolescent vaccines market
  • Patient-based forecasts for key vaccine classes and products according to recommended vaccination groups and coverage rates in the seven major markets
  • In-depth discussion of novel vaccine pipeline candidates and discussion of their future potential


    • Report Highlights
    Driven by the launch of novel, high-price vaccines such as Gardasil or RotaTeq, the pediatric and adolescent vaccines market is experiencing a rapid growth. Wyeth's Prevnar has emerged as the first blockbuster vaccine, demonstrating that innovative vaccines can command high prices and yield high revenues in the pediatric vaccines market.

    The main future opportunities lie in the pneumococcal, meningococcal and HPV vaccine sectors, where there is a large medical need. Particularly a vaccine against infections with N. meningitidis B would have a potentially huge commercial.

    Key challenges include the reluctance of healthcare providers to pay for increasingly expensive vaccines and the lack of widespread organized vaccination programs for school children and teenagers. With an increasing focus on adolescent vaccines such as Gardasil or Menactra, better ways to reach adolescents for vaccination will have to be found.


    Reasons to Purchase

  • Review clinical and commercial factors driving new product decisions and the strategies of key players in the pediatric and adolescent vaccines market
  • Gain insight through a patient-based forecast and a thorough analysis of marketed and pipeline products as well as case studies in key vaccine classes
  • Understand concerns, unmet needs and future opportunities by learning about the views of key pediatric and adolescent vaccine opinion leaders

    • Table of Contents

    Other users found this report page using the following search terms: vaccines DTaP hepatitis MMR polio synflorix streptorix rise acwysanofi pasteur vaccines gsk spread 13vpncwyeth geographical

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.